The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. (2019)

First Author: Drexler B
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3324/haematol.2018.200014

PubMed Identifier: 30409796

Publication URI: http://europepmc.org/abstract/MED/30409796

Type: Journal Article/Review

Volume: 104

Parent Publication: Haematologica

Issue: 4

ISSN: 0390-6078